|
Real-time Estimate
Cboe BZX
07:47:41 08/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 727.59 USD | -1.96% |
|
-0.54% | -5.31% |
| Market Cap | 7.41TCr 6.62TCr 6.18TCr 5.61TCr 11TCr 7,16900Cr 11TCr 74TCr 29TCr 3,64600Cr 28TCr 27TCr 11,72000Cr | P/E 2026 * |
16.6x | P/E 2027 * | 14.7x |
|---|---|---|---|---|---|
| Enterprise Value | 6.66TCr 5.95TCr 5.55TCr 5.05TCr 9.5TCr 6,44500Cr 9.57TCr 67TCr 26TCr 3,27800Cr 25TCr 24TCr 10,53800Cr | EV / Sales 2026 * |
3.88x | EV / Sales 2027 * | 3.41x |
| Free-Float |
71.06% | Yield 2026 * |
0.53% | Yield 2027 * | 0.59% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Tradegate
| RGO | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Xetra
| RGO | End-of-day quote | |
|
London S.E.
| 0R2M | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Boerse Muenchen
| RGO | Real-time | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -1.90% | ||
| 1 week | -0.54% | ||
| Current month | -3.62% | ||
| 1 month | -9.81% | ||
| 3 months | +10.25% | ||
| 6 months | -5.76% | ||
| Current year | -5.31% |
| 1 week | 722.02 |  | 753.68 |
| 1 month | 722.02 | | 813.53 |
| Current year | 591.52 | | 859.34 |
| 1 year | 541 | | 859.34 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
George Sing
BRD | Director/Board Member | 76 | 08/01/1988 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/09/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 02/09/26 | Exercice | Director | 1,200 | 0.0012% | ||
| 19/08/26 | Exercice | General Counsel | 33,583 | 0.0326% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.96% | -0.54% | +29.62% | -12.14% | 7.41TCr | |
| -3.42% | +0.79% | +37.04% | +102.70% | 1,06000Cr | |
| -1.93% | -1.08% | +34.89% | +61.39% | 62TCr | |
| -1.08% | +3.98% | +16.89% | +81.27% | 48TCr | |
| -1.92% | -1.80% | +63.45% | +35.14% | 35TCr | |
| -1.36% | +2.06% | +22.28% | +42.00% | 35TCr | |
| -1.87% | +0.29% | +11.17% | +34.35% | 27TCr | |
| -1.74% | -2.07% | -5.90% | +10.78% | 25TCr | |
| -2.59% | -0.18% | +37.98% | +49.71% | 22TCr | |
| -1.07% | -0.51% | +24.10% | +95.51% | 18TCr | |
| Average | -1.88% | -0.65% | +27.15% | +50.07% | 38.62TCr | |
| Weighted average by Cap. | -2.15% | -0.00% | +29.98% | +65.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.72TCr 1.53TCr 1.43TCr 1.3TCr 2.45TCr 1,66100Cr 2.47TCr 17TCr 6.72TCr 84TCr 6.45TCr 6.31TCr 2,71600Cr | 1.85TCr 1.65TCr 1.54TCr 1.4TCr 2.64TCr 1,79200Cr 2.66TCr 19TCr 7.25TCr 91TCr 6.95TCr 6.8TCr 2,92900Cr |
| Net income | 495.16Cr 442.43Cr 412.77Cr 374.93Cr 706.13Cr 48TCr 711.4Cr 4.96TCr 1.94TCr 24TCr 1.86TCr 1.82TCr 78TCr | 548.58Cr 490.16Cr 457.3Cr 415.37Cr 782.3Cr 53TCr 788.15Cr 5.5TCr 2.15TCr 27TCr 2.06TCr 2.01TCr 87TCr |
| Net Debt | -747.51Cr -667.9Cr -623.13Cr -566Cr -1.07TCr -72TCr -1.07TCr -7.49TCr -2.93TCr -37TCr -2.81TCr -2.75TCr -1,18200Cr | -1.1TCr -978.45Cr -912.86Cr -829.17Cr -1.56TCr -1,05900Cr -1.57TCr -11TCr -4.29TCr -54TCr -4.11TCr -4.02TCr -1,73200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/26/08 | $730.00 | -1.63% | 47,939 |
| 07/26/07 | $742.12 | +0.46% | 6,26,433 |
| 06/26/06 | $738.72 | +1.69% | 6,15,062 |
| 05/26/05 | $726.47 | -1.19% | 6,95,028 |
| 02/26/02 | $735.20 | +0.05% | 6,13,949 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
